We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
SemBioSys Enters Into Commercialization and Supply Agreement for Plant-Made Chymosin Protein
News

SemBioSys Enters Into Commercialization and Supply Agreement for Plant-Made Chymosin Protein

SemBioSys Enters Into Commercialization and Supply Agreement for Plant-Made Chymosin Protein
News

SemBioSys Enters Into Commercialization and Supply Agreement for Plant-Made Chymosin Protein

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "SemBioSys Enters Into Commercialization and Supply Agreement for Plant-Made Chymosin Protein"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

SemBioSys Genetics Inc. has announced that it has entered into an exclusive commercial license agreement with Instituto de Agrobiotecnologia Rosario S.A. (INDEAR).

The agreement pertains to the commercialization and supply of SemBioSys’ safflower-produced chymosin, a protein used in the manufacture of food products. INDEAR signed an option agreement with SemBioSys in January 2008 to evaluate the utility of using SemBioSys’ plant-based technology for the production of chymosin.

In exchange for an upfront technology access fee, SemBioSys has granted INDEAR an exclusive royalty-bearing license to SemBioSys’ technology in Argentina. INDEAR will use SemBioSys’ technology to extract chymosin from modified safflower seeds and sell the protein for use in the manufacture of cheese in Argentina.

Under the terms of the agreement, SemBioSys has granted INDEAR a time-limited right of first refusal to expand the territory beyond Argentina. Financial terms of the agreement were not disclosed.

“Chymosin is one of the first transgenic products developed by SemBioSys. INDEAR is an ideal partner to work with us to launch the product,” said James Szarko, President and CEO of SemBioSys. “This transaction is an example of SemBioSys’ strategy to partner existing non-pharmaceutical programs to accelerate commercialization without deviating from our core areas of focus: the development of Biosimilar Insulin and Apo AIMilano. This commercialization agreement is another validation of SemBioSys’ platform technology as a versatile, scalable, and cost effective protein production system. It also helps to secure future revenue streams based on our non-pharmaceutical products.”

Chymosin is a natural protein, historically derived from calves, used in the production of cheese. The majority of chymosin used today is produced via fermentation in E. coli or fungi. Using its proprietary plant expression system, SemBioSys has developed animal-free, kosher-quality chymosin and an extraction process that will allow for the production of chymosin in plants at a significantly reduced cost.
Advertisement